Compartir
Neocarzinostatin: The Past, Present, and Future of Anticancer Drug (en Inglés)
Maeda, Hiroshi ; Edo, Kiyoto ; Ishida, Nakao (Autor)
·
Springer
· Tapa Blanda
Neocarzinostatin: The Past, Present, and Future of Anticancer Drug (en Inglés) - Maeda, Hiroshi ; Edo, Kiyoto ; Ishida, Nakao
$ 138.676
$ 231.126
Ahorras: $ 92.450
Elige la lista en la que quieres agregar tu producto o crea una nueva lista
✓ Producto agregado correctamente a la lista de deseos.
Ir a Mis Listas
Origen: Estados Unidos
(Costos de importación incluídos en el precio)
Se enviará desde nuestra bodega entre el
Viernes 16 de Agosto y el
Viernes 30 de Agosto.
Lo recibirás en cualquier lugar de Argentina entre 1 y 3 días hábiles luego del envío.
Reseña del libro "Neocarzinostatin: The Past, Present, and Future of Anticancer Drug (en Inglés)"
The 20th century has witnessed the great benefits of the development of antibi- otics, which became a reality after World War IL More than 50 years ago I witnessed the miraculous therapeutic power of penicillin, when I was a student at the Tohoku University Medical School's Department of Bacteriology in Sendai, Japan. The late Dr. Kondo was a graduate student in the department at that time and developed the first crude penicillin preparation in Japan which was applied with dramatic results in two patients. Although there was patient-family consent at that time, ethics committees, randomization. mutagenesis tests, distribution studies, purity-criteria, and phar- macokinetics were not yet in existence. Today, regulatory procedures have com- plicated the whole drug-approval process. For example, any new antibiotics that have been proven effective in laboratory studies against gram-negative bacteria, as might exist in deadly plague bacteria, must still undergo a long and enormously costly regulatory process before they can be introduced to benefit society, and before government insurance can be applied.
